Francis Duhay sold $123 of NVNO
director at enVVeno Medical Corp. 11 shares at an average of $11.21, traded Sep 11, 2026, filed Sep 14, 2026.
Score components
- +15RoleDirector
- 0Trade size$123 at market
- 0Share of holdings soldSold 0.5% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-042629, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | SOpen-market sale Common Stock10b5-1 | -11 | $11.21 | $123 | 2,351 | 29 d ago |
Related signals
Other insiders at enVVeno Medical Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | enVVeno Medical Corp | Francis Duhay director | $1,443 140 shares | -6% | |
| 0Weak | enVVeno Medical Corp | Francis Duhay director | $1,613 140 shares | -5% | |
| 0Weak | enVVeno Medical Corp | Francis Duhay director | $1,742 4,900 shares | -5% | |
| 0Weak | enVVeno Medical Corp | Francis Duhay director | $4,067 4,900 shares | -5% | |
| 53Moderate | enVVeno Medical Corp | Francis Duhay director | $250k 81,433 shares | +389% | |
| 36Weak | enVVeno Medical Corp | Robert Gray director | $10k 3,500 shares | +46% | |
| 40Moderate | enVVeno Medical Corp | Sanjay Shrivastava director | $16k 5,400 shares | +139% | |
| 40Moderate | enVVeno Medical Corp | Matthew Jenusaitis director | $24k 9,620 shares | +139% | |
| 48Moderate | enVVeno Medical Corp | Robert Andrew Berman Chief Executive Officer | $31k 12,000 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.